Avicanna Inc CEO Aras Azadian joined Proactive's Natalie Stoberman with the company's Year in Review including milestones reached in 2022.
Azadian said 2022 was challenging for both the biopharmaceutical and cannabis industries. Despite the challenges, Azadian said it was transformational year for Avicanna as it remained focused and deliver on its business plan.
Avicanna's aim in 2022 was to commercialize and advance the intellectual property portfolio across its four business units: Active Pharmaceutical Ingredients, Cosmetics, Medical, and Pharmaceutical, which contributed to successful exports to 18 international markets.
View source version on newsdirect.com: https://newsdirect.com/news/avicanna-says-2022-was-transformational-despite-challenging-cannabis-market-686582899